Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai
Table 1
Resistance to second-line drugs among MDR-TB patients by demographic characteristics and disease profile.
Variables
Total
Resistance to at least one SLD ()
Resistance to Ofx ()
Resistance to Am/Km ()
Resistant to Cm ()
XDR-TB ()
%
%
%
%
%
Age at diagnosis (years)
<30
48
17
35.4
12
25.0
3
6.3
6
12.5
3
6.3
30–60
137
77
56.2
58
43.2
26
19.0
30
21.9
21
15.3
>60
32
24
75.0
20
62.5
8
25.0
8
25.0
6
18.8
value
<0.001
<0.001
0.02
0.14
0.09
Sex
Male
157
84
53.5
63
40.1
28
17.8
32
20.4
21
13.4
Female
60
34
56.7
27
45.0
9
15.0
12
20.0
9
15.0
value
0.68
0.51
0.62
0.95
0.76
Domestic migrant
No
131
77
58.8
61
46.6
30
22.9
30
22.9
24
18.3
Yes
86
41
47.7
29
33.7
7
8.1
14
16.3
6
7.0
value
0.11
0.06
0.005
0.24
0.02
Hospital of tuberculosis diagnosis
Municipal level hospital
127
77
60.6
70
55.1
25
19.7
20
15.7
22
17.3
District level hospital
85
36
42.4
16
18.8
11
12.9
22
25.9
7
8.2
value
0.003
<0.001
0.20
0.07
0.06
History of tuberculosis treatment
Newly diagnosed
80
37
46.3
29
36.3
16
20.0
17
21.3
14
17.5
Relapsed
89
47
52.8
37
41.6
10
11.2
15
16.9
9
10.1
Chronic
48
34
70.8
24
50.0
11
22.9
12
25.0
7
14.6
value
0.01
0.13
0.91
0.74
0.50
SLDs, second-line drugs; Ofx, ofloxacin; Am, amikacin; Km, kanamycin; Cm, capreomycin; XDR-TB, extensively drug-resistant tuberculosis. Mantel-Haenszel chi-square test. Five patients diagnosed in general hospitals were excluded.
